Compare Moderna, Inc. (MRNA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Vanguard S&P 500 ETF — how do they compare? Moderna, Inc. trades at $137.39 (market cap $56.02B), while Vanguard S&P 500 ETF trades at $702.25. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| MRNA | VOO | |
|---|---|---|
Market Cap | $56.02B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $174.38 | $714.90 |
52-Week Low | $22.36 | $580.93 |
Enterprise Value | $52.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
VOO trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. Support is firm near $701, while resistance sits at $707. The ETF remains a core S&P 500 holding, with recent news highlighting its tax efficiency versus gold ETFs and strong inflows amid record ETF launches in 2026.
Long-term outlook remains positive given historical S&P 500 performance, though risks include elevated market valuations and Fed policy uncertainty. The ETF offers broad market exposure, but investors face potential volatility from macroeconomic factors and high concentration in top AI-driven companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
